This study explored the change in risk of thromboembolism in patients randomised to receive either 4-factor prothrombin complex concentrate or fresh frozen plasma, using pooled data from two studies.
Background: Plasma is commonly used for vitamin K antagonist (VKA) reversal, but observational studies suggest that it is associated with transfusion-related adverse reactions (e.g., volume overload). However, this issue has not previously been addressed in a randomized controlled trial (RCT).
Discover the latest in oral anticoagulation and its reversal, including the use of 3-factor and 4-factor prothrombin complex concentrate (PCC) and more.
Review our recent article 'Reversal of warfarin-associated major haemorrhage: activated prothrombin complex concentrate versus 4-factor prothrombin complex concentrate.
This study compared data from two phase IIIb randomised controlled trials to assess the relative risk of volume overload occurring as a result of plasma versus 4F-PCC administration.
Urgent reversal of warfarin is required for patients who experience major bleeding or require urgent surgery. Treatment options include the combination of vitamin K and coagulation factor replacement with either prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP).
Recent publications will be reviewed and distilled into key learning points for your convenience, sorted by year of publication.
This review article examines the current evidence for reversal of non-vitamin K oral anticoagulants.
Objectives: We assessed the benefits and harms of PCC compared with fresh frozen plasma in the acute medical and surgical setting involving vitamin K antagonist-treated bleeding and non-bleeding patients.
This retrospective study of 63 patients taking warfarin who presented at a level 1 trauma centre and required emergency neurological procedures attempts to determine the difference in thrombotic complication rate following anticoagulation reversal with prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP).